Navigation Links
PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Date:10/5/2007

- New Pediatric Data Presented at 21st North American Cystic Fibrosis

Conference Confirm Previous Findings in Adult population -

SOUTH PLAINFIELD, N.J., Oct. 5 /PRNewswire / -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced encouraging data from a Phase 2 clinical trial of PTC124 in pediatric patients with cystic fibrosis (CF) due to a nonsense mutation. These pediatric results and additional information emerging from long-term studies support the existing data from prior short- term studies in adult CF patients. These studies show that treatment with PTC124 results in statistically significant improvements in a measure of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. These data were highlighted today in a plenary session entitled "CF Drug Development: What's New?" given by Dr. Felix Ratjen, University of Toronto Professor of Pediatrics and Respiratory Medicine Division Chief, at the 21st North American Cystic Fibrosis Conference in Anaheim, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

Patients with CF lack the CFTR protein, a chloride channel that maintains proper hydration of epithelial cells in the lung, pancreas, and liver. PTC has completed multi-site, open-label, dose-ranging Phase 2 clinical trials in adult CF patients to determine whether PTC124 can induce production of active CFTR protein. Studies in the U.S. and Israel evaluated nasal transepithelial potential difference (TEPD) as a surrogate for CFTR protein production in adult CF patients. Across the two studies, at both PTC124 dose levels tested, TEPD assessments showed statistically significant (p<0.03) improvements of mean CFTR-dependent chloride secretion i
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: ... that it is filing for two medical marijuana dispensary locations ... are in addition to the Clark County, Nevada ... special use permit, as previously announced.  GrowBLOX Sciences, ... be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5
... in Physical ... Quality of Life, SAN FRANCISCO, Oct. 27 ... injections of golimumab (CNTO 148),50 mg and 100 mg, ... skin symptoms of active psoriatic arthritis,through six months with ...
... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced ... that repeat administration with TRU-015 continues to ... arthritis,(RA) signs and symptoms based on American ... positive results following preliminary,analyses from a Phase ...
... MuriGen Therapeutics,today announced that its collaboration with ... drugs that target arthritis and other inflammatory diseases,has ... in February 2006 by MuriGen,Therapeutics and Zenyth Therapeutics ... therapeutic antibodies that inhibit the activity of the,cytokine ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 2WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 3
(Date:7/23/2014)... world by 2050, according to one of the scenarios ... may be advantageous to the physiology and the biochemical ... plants such as Stylosanthes capitata Vogel , a ... as Brazil., The conclusion is from a study carried ... the Ribeiro Preto Faculty of Philosophy, Sciences and Languages ...
(Date:7/23/2014)... SUP05 will play an increasingly important role in carbon ... minimum zones expand, according to research published this week ... Sciences . , University of British Columbia researchers plumbed ... Inlet, to chart how microbial community metabolism changes as ... very detailed picture of how SUP05 a bacterial ...
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Scientists are reporting the first-ever data to show that ... function of heart cells, and that loss of the protein ... Published Feb. 26 in the Journal of Biological ... online Feb. 19, the research was led by scientists at ...
... on Antarctica,s rich marine life are presented this week ... (AAAS). Marine Biologist Huw Griffiths from British Antarctic Survey ... the distribution and abundance of Antarctica,s vast marine biodiversity ... Griffiths presents results from the census which began ...
... BETHESDA, Md. (Feb. 16, 2010) A few minor ... endurance, according to a new study from Physiological Genomics ... more likely to have variations of the NRF2 gene than ... have the genetic variations compared to sprinters, although the difference ...
Cached Biology News:Scientists identify critical enzyme in healthy heart function 2Understanding global climate change through new breakthroughs in polar research 2Study finds variations in 1 gene may be associated with endurance running 2
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... [14C] Methylated Protein Molecular Weight Markers, ... proteins enable molecular weight determination of the ... allows visual monitoring of band migration in ... activity of the [14C] version without Rainbow-labeling ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
Biology Products: